Published in FEBS Lett on October 10, 2005
NF-kappaB is a negative regulator of IL-1beta secretion as revealed by genetic and pharmacological inhibition of IKKbeta. Cell (2007) 4.56
Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases. Pharmacol Rev (2010) 1.97
Neutrophil elastase in cyclic and severe congenital neutropenia. Blood (2006) 1.74
Annexin 1 cleavage in activated neutrophils: a pivotal role for proteinase 3. J Biol Chem (2007) 1.10
Rats and mice immunised with chimeric human/mouse proteinase 3 produce autoantibodies to mouse Pr3 and rat granulocytes. Ann Rheum Dis (2007) 1.07
Human neutrophil elastase responsive delivery from poly(ethylene glycol) hydrogels. Biomacromolecules (2009) 1.07
Anti-PR3 immune responses induce segmental and necrotizing glomerulonephritis. Clin Exp Immunol (2009) 1.04
Structural characterization of mouse neutrophil serine proteases and identification of their substrate specificities: relevance to mouse models of human inflammatory diseases. J Biol Chem (2009) 1.01
Activation of the unfolded protein response is associated with impaired granulopoiesis in transgenic mice expressing mutant Elane. Blood (2011) 0.93
Discrimination and variable impact of ANCA binding to different surface epitopes on proteinase 3, the Wegener's autoantigen. J Autoimmun (2010) 0.91
A rapid Flp-In system for expression of secreted H5N1 influenza hemagglutinin vaccine immunogen in mammalian cells. PLoS One (2011) 0.89
Characterization of human pre-elafin mutants: full antipeptidase activity is essential to preserve lung tissue integrity in experimental emphysema. Biochem J (2007) 0.85
α-1-antitrypsin variants and the proteinase/antiproteinase imbalance in chronic obstructive pulmonary disease. Am J Physiol Lung Cell Mol Physiol (2015) 0.83
Identification and characterization of circulating variants of CXCL12 from human plasma: effects on chemotaxis and mobilization of hematopoietic stem and progenitor cells. Stem Cells Dev (2014) 0.80
Proteases and protease inhibitors of urinary extracellular vesicles in diabetic nephropathy. J Diabetes Res (2015) 0.80
ANCA-associated vasculitis - clinical utility of using ANCA specificity to classify patients. Nat Rev Rheumatol (2016) 0.80
Dysregulation of autoantigen genes in ANCA-associated vasculitis involves alternative transcripts and new protein synthesis. J Am Soc Nephrol (2014) 0.79
Alpha-1 antitrypsin reduces severity of pseudomonas pneumonia in mice and inhibits epithelial barrier disruption and pseudomonas invasion of respiratory epithelial cells. Front Public Health (2013) 0.77
N-Formyl-Perosamine Surface Homopolysaccharides Hinder the Recognition of Brucella abortus by Mouse Neutrophils. Infect Immun (2016) 0.75
2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum (2013) 11.18
Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med (2009) 6.72
Anticytoplasmic autoantibodies: their immunodiagnostic value in Wegener granulomatosis. Ann Intern Med (1989) 3.33
A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis Rheum (2001) 3.15
Rituximab treatment of idiopathic membranous nephropathy. Kidney Int (2007) 2.85
Proteinase 3 and neutrophil elastase enhance inflammation in mice by inactivating antiinflammatory progranulin. J Clin Invest (2008) 2.77
Antineutrophil cytoplasmic antibodies. Arthritis Rheum (1998) 2.53
Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases. Pharmacol Rev (2010) 1.97
ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis. Am J Med (2007) 1.94
Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener autoantigen) are pathogenic in vivo. Blood (2004) 1.91
MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies. J Exp Med (2013) 1.88
Role of Lkb1, the causative gene of Peutz-Jegher's syndrome, in embryogenesis and polyposis. Proc Natl Acad Sci U S A (2002) 1.83
Antineutrophil cytoplasmic antibodies reacting with the pro form of proteinase 3 and disease activity in patients with Wegener's granulomatosis and microscopic polyangiitis. Arthritis Rheum (2001) 1.76
Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. Ann Intern Med (2007) 1.73
Recurrence of ANCA-associated vasculitis following renal transplantation in the modern era of immunosupression. Kidney Int (2007) 1.60
A study of a weight-adjusted aprotinin dosing schedule during cardiac surgery. Anesth Analg (2002) 1.56
Characterization of blood borne microparticles as markers of premature coronary calcification in newly menopausal women. Am J Physiol Heart Circ Physiol (2008) 1.44
Lesions of the respiratory tract associated with the finding of anti-neutrophil cytoplasmic autoantibodies with a perinuclear staining pattern. Mayo Clin Proc (1994) 1.37
Integrin and Arg-Gly-Asp dependence of cell adhesion to the native and unfolded triple helix of collagen type VI. Exp Cell Res (1993) 1.33
Mutation of a novel gene results in abnormal development of spermatid flagella, loss of intermale aggression and reduced body fat in mice. Genetics (2002) 1.29
Lung toxicity associated with cyclophosphamide use. Two distinct patterns. Am J Respir Crit Care Med (1996) 1.27
Cutaneous Wegener's granulomatosis: clinical, histopathologic, and immunopathologic features of thirty patients. J Am Acad Dermatol (1994) 1.23
Cocaine-induced midline destructive lesions: clinical, radiographic, histopathologic, and serologic features and their differentiation from Wegener granulomatosis. Medicine (Baltimore) (2001) 1.22
Antineutrophil cytoplasmic antibodies reacting with human neutrophil elastase as a diagnostic marker for cocaine-induced midline destructive lesions but not autoimmune vasculitis. Arthritis Rheum (2004) 1.15
Tracheobronchial involvement in Wegener's granulomatosis. Am J Respir Crit Care Med (1995) 1.13
Tailor-made inflammation: how neutrophil serine proteases modulate the inflammatory response. J Mol Med (Berl) (2010) 1.13
Comparison of disease activity measures for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis. Ann Rheum Dis (2008) 1.12
Alterations in platelet function and cell-derived microvesicles in recently menopausal women: relationship to metabolic syndrome and atherogenic risk. J Cardiovasc Transl Res (2011) 1.11
Granzyme H destroys the function of critical adenoviral proteins required for viral DNA replication and granzyme B inhibition. EMBO J (2007) 1.09
Crystal structure of the apoptosis-inducing human granzyme A dimer. Nat Struct Biol (2003) 1.03
NSP4, an elastase-related protease in human neutrophils with arginine specificity. Proc Natl Acad Sci U S A (2012) 1.03
The 2.2-A crystal structure of human pro-granzyme K reveals a rigid zymogen with unusual features. J Biol Chem (2002) 1.01
Differential expression of the granzymes A, K and M and perforin in human peripheral blood lymphocytes. Int Immunol (2005) 1.00
Global substrate profiling of proteases in human neutrophil extracellular traps reveals consensus motif predominantly contributed by elastase. PLoS One (2013) 1.00
Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol (2014) 0.99
Killing of target cells by redirected granzyme B in the absence of perforin. FEBS Lett (2004) 0.99
Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum (2013) 0.98
A hydrophobic patch on proteinase 3, the target of autoantibodies in Wegener granulomatosis, mediates membrane binding via NB1 receptors. J Biol Chem (2008) 0.98
Membrane receptors are not required to deliver granzyme B during killer cell attack. Blood (2004) 0.97
Natural killer cell-derived human granzyme H induces an alternative, caspase-independent cell-death program. Blood (2007) 0.96
Capture-ELISA based on recombinant PR3 is sensitive for PR3-ANCA testing and allows detection of PR3 and PR3-ANCA/PR3 immunecomplexes. J Immunol Methods (1998) 0.96
Warfarin or low-molecular-weight heparin therapy does not prolong pig-to-primate cardiac xenograft function. Am J Transplant (2005) 0.96
Cloning and functional expression of the murine homologue of proteinase 3: implications for the design of murine models of vasculitis. FEBS Lett (1997) 0.95
Proteinase 3-dependent caspase-3 cleavage modulates neutrophil death and inflammation. J Clin Invest (2014) 0.95
Neutrophils require SHP1 to regulate IL-1β production and prevent inflammatory skin disease. J Immunol (2010) 0.95
The low-penetrance R92Q mutation of the tumour necrosis factor superfamily 1A gene is neither a major risk factor for Wegener's granulomatosis nor multiple sclerosis. Ann Rheum Dis (2007) 0.94
A proportion of proteinase 3 (PR3)-specific anti-neutrophil cytoplasmic antibodies (ANCA) only react with PR3 after cleavage of its N-terminal activation dipeptide. Clin Exp Immunol (1998) 0.94
Interlobar variation in the recovery of bronchoalveolar lavage fluid, cell populations, and angiotensin-converting enzyme in normal volunteers. J Lab Clin Med (1993) 0.92
Effective antiplatelet therapy does not prolong transgenic pig to baboon cardiac xenograft survival. Xenotransplantation (2004) 0.92
Discrimination and variable impact of ANCA binding to different surface epitopes on proteinase 3, the Wegener's autoantigen. J Autoimmun (2010) 0.91
Granzyme B delivery via perforin is restricted by size, but not by heparan sulfate-dependent endocytosis. Proc Natl Acad Sci U S A (2008) 0.91
NSP4 is stored in azurophil granules and released by activated neutrophils as active endoprotease with restricted specificity. J Immunol (2013) 0.91
Successful induction of remission with rituximab for relapse of ANCA-associated vasculitis post-kidney transplant: report of two cases. Am J Transplant (2007) 0.91
Recombinant expression and properties of the Kunitz-type protease-inhibitor module from human type VI collagen alpha 3(VI) chain. Eur J Biochem (1994) 0.91
Mapping of conformational epitopes on human proteinase 3, the autoantigen of Wegener's granulomatosis. J Immunol (2010) 0.90
Recombinant proteinase 3 produced in different expression systems: recognition by anti-PR3 antibodies. J Immunol Methods (2000) 0.88
Interaction of proteinase 3 with CD11b/CD18 (beta2 integrin) on the cell membrane of human neutrophils. J Leukoc Biol (2003) 0.87
Cocaine-induced midline destructive lesions - an autoimmune disease? Autoimmun Rev (2012) 0.85
Delivery and therapeutic potential of human granzyme B. Immunol Rev (2010) 0.85
Expression of type VI collagen mRNA during wound healing. J Invest Dermatol (1993) 0.85
Effects of carboxy-terminal modifications of proteinase 3 (PR3) on the recognition by PR3-ANCA. Kidney Int (2003) 0.85
Myofibrillar myopathy with arrhythmogenic right ventricular cardiomyopathy 7: corroboration and narrowing of the critical region on 10q22.3. Eur J Hum Genet (2008) 0.84
Immunohistochemical localization of collagen VI in diabetic glomeruli. Kidney Int (1994) 0.83
Diabetes insipidus and anterior pituitary insufficiency as presenting features of Wegener's granulomatosis. Am J Kidney Dis (2001) 0.83
Functional characterization of antineutrophil cytoplasmic antibodies in patients with cocaine-induced midline destructive lesions. Arthritis Rheum (2008) 0.82
A novel capture-ELISA for detection of anti-neutrophil cytoplasmic antibodies (ANCA) based on c-myc peptide recognition in carboxy-terminally tagged recombinant neutrophil serine proteases. J Immunol Methods (2005) 0.82
The "normal" factor VIII concentration in plasma. Thromb Res (2010) 0.82
Neutrophil proteinase 3 and dipeptidyl peptidase I (cathepsin C) as pharmacological targets in granulomatosis with polyangiitis (Wegener granulomatosis). Semin Immunopathol (2013) 0.82
[Cocaine, ANCA, and Wegener's granulomatosis]. Pathologica (2001) 0.80
Functional significance of Asn-linked glycosylation of proteinase 3 for enzymatic activity, processing, targeting, and recognition by anti-neutrophil cytoplasmic antibodies. J Biochem (2006) 0.80
Anti-neutrophil cytoplasmic autoantibodies. N Engl J Med (1988) 0.80
Perspectives and potential roles for the newly discovered NSP4 in the immune system. Expert Rev Clin Immunol (2012) 0.80
A monoclonal antibody (MCPR3-7) interfering with the activity of proteinase 3 by an allosteric mechanism. J Biol Chem (2013) 0.79
Physical and enzymatic perturbation of the architecture of the Tunica media destroys its inherent thromboresistance. Thromb Haemost (2002) 0.79
Gold fluorescent annexin A5 as a novel apoptosis detection tool. Cytometry A (2009) 0.79
Role of testing for anticytoplasmic autoantibodies in the differential diagnosis of scleritis and orbital pseudotumor. Mayo Clin Proc (1990) 0.79
Are antineutrophil cytoplasmic antibodies pathogenic? Experimental approaches to understand the antineutrophil cytoplasmic antibody phenomenon. Rheum Dis Clin North Am (2001) 0.79
Relevance of the mouse model as a therapeutic approach for neutrophil proteinase 3-associated human diseases. Int Immunopharmacol (2013) 0.79
Influence of anatomical location on arterial thrombosis. Arterioscler Thromb Vasc Biol (2002) 0.78
Variability of plasma aprotinin concentrations in pediatric patients undergoing cardiac surgery. J Thorac Cardiovasc Surg (2004) 0.78
Cell adhesion to type-VI collagen. Biochem Soc Trans (1991) 0.77
Antineutrophil cytoplasmic antibodies: are they pathogenic? Clin Exp Rheumatol (2004) 0.77
Agreement of anti-neutrophil cytoplasmic antibody measurements obtained from serum and plasma. Clin Exp Immunol (2006) 0.77
Glycosylation of proteinase 3 (PR3) is not required for its reactivity with antineutrophil cytoplasmic antibodies (ANCA) in Wegener's granulomatosis. Clin Exp Rheumatol (2009) 0.76
Reduced high shear platelet adhesion to the vascular media: defective von Willebrand factor binding to the interstitial collagen. Thromb Haemost (2002) 0.76
A prospective, randomized platelet-function study of heparinized oxygenators and cardiotomy suction. J Cardiothorac Vasc Anesth (2006) 0.76
Part 2: Synopsis of B-lymphocyte targeted therapy of ANCA-associated vasculitis. Clin Exp Rheumatol (2007) 0.76
Nasal biopsy in Wegener's granulomatosis. Hum Pathol (1991) 0.75